W.-H. Chen

Utilization of Eco-friendly Imidazolium-Based Ionic Liquids for Gluten Extraction: Investigating the Influence of Side Chains and Anions

This paper investigates the use of imidazolium-based ionic liquids for gluten extraction, finding that 1% [C5DMIM][OMs]aq effectively dissolves gluten without altering its structure or antibody binding.

CspZ FH-binding sites as epitopes promote antibody-mediated Lyme borreliae clearance

The paper shows that antibodies targeting CspZ FH-binding sites effectively clear Lyme borreliae in vitro and in vivo, highlighting their importance for vaccine development.

A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model

This study evaluates a SARS-CoV-2 Spike ferritin nanoparticle vaccine in cynomolgus macaques, showing strong immunological responses and protection against infection.

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters

This study evaluates a SARS-CoV-2 spike ferritin nanoparticle vaccine's effectiveness against B.1.1.7 and B.1.351 variants in hamsters, showing protection against disease and viral replication.

A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells

This study evaluates a spike-ferritin nanoparticle vaccine with adjuvants, showing enhanced T cell responses and cross-reactivity against SARS-CoV and other coronaviruses.

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

This study evaluates an adjuvanted SARS-CoV-2 RBD nanoparticle vaccine in macaques, showing robust immune responses and protection against viral challenge and variants.

Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

A SARS-CoV-2 Spike ferritin nanoparticle vaccine induces broad neutralizing antibodies and protects nonhuman primates against respiratory infection and disease.

Process Development and Scale-up Optimization of the SARS-CoV-2 Receptor Binding Domain-Based Vaccine Candidate, RBD219-N1C1

The paper optimizes the production process for a SARS-CoV-2 vaccine candidate, achieving high yield and purity through yeast fermentation and chromatographic purification.

Genetic Modification to Design a Stable Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain as a COVID-19 Vaccine Candidate

The paper genetically modifies SARS-CoV-2 RBD variants in yeast to identify a more stable and manufacturable vaccine candidate.

SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice

This study develops a yeast-expressed SARS-CoV-2 RBD protein vaccine candidate, RBD219-N1C1, which induces neutralizing antibodies and T-cell responses in mice.

Single-molecule light-sheet microscopy with local nanopipette delivery

This paper introduces ldSPIM, a method combining light sheet microscopy with nanopipette delivery to precisely deliver single molecules to cells and image their effects in real-time.

Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement

This paper develops a SARS-CoV subunit vaccine using yeast-expressed RBD219-N1 with Alhydrogel® and shows it provides full protection against SARS-CoV challenge in mice.

A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein

The paper reports the high-resolution structure of the SARS-CoV-2 Spike RBD and identifies a conserved epitope accessible in open conformations, which is targeted by cross-reactive antibodies.

Alterations of human lung and gut microbiome in non-small cell lung carcinomas and distant metastasis

This study examines microbiome changes in lung and gut of NSCLC patients and finds sputum microbiota better predicts disease and metastasis than gut microbiota, with machine learning models achieving 0.842 AUC.